Clinical guidelines address HCT, GVHD workup and management | WHO, CDC report on increase in measles cases, deaths | WHO: Death toll tops 5K in DRC's measles epidemic
December 6, 2019
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
Top Story
Clinical guidelines address HCT, GVHD workup and management
The National Comprehensive Cancer Network has published new clinical practice guidelines for evaluation of patients who before hematopoietic cell transplantation. The document also includes a treatment algorithm and addresses identification and management of acute and chronic graft-versus-host disease.
Targeted Oncology (12/4) 
LinkedIn Twitter Facebook Email
Improve your platelet safety
Unsafe platelets can have serious consequences. Improve platelet safety with the Platelet PGD test: Reduce the risk of bacterial contamination and ensure that platelets are safe to use on day six or day seven. That's peace of mind you can count on. Read more.
Science & Health
WHO, CDC report on increase in measles cases, deaths
WHO, CDC report on increase in measles cases, deaths
(Sean Gallup/Getty Images)
The World Health Organization reported that measles cases around the world rose from 7,585,900 in 2017 to 9,769,400 in 2018, while measles-related deaths increased from 124,000 to 142,300 during the same period, with most deaths involving unvaccinated children. Meanwhile, a CDC study in the agency's Morbidity and Mortality Weekly Report showed that although yearly global measles incidence and deaths dropped between 2000 and 2018 and vaccination prevented 23.2 million deaths during that period, the number of infections and deaths have increased since 2016.
Reuters (12/6),  Physician's Briefing/HealthDay News (12/5) 
LinkedIn Twitter Facebook Email
WHO: Death toll tops 5K in DRC's measles epidemic
The World Health Organization reported Thursday that at least 5,000 people have died from a measles epidemic this year in the Democratic Republic of Congo, many of them children. Factors such as high malnutrition levels and low immunization rates have contributed to the spread of the disease.
Reuters (12/5) 
LinkedIn Twitter Facebook Email
Emerging Trends
GAVI to stockpile 500K Merck Ebola vaccine doses for emergency use
The global vaccine alliance GAVI will stockpile 500,000 doses of Merck's Ervebo Ebola vaccine for future outbreaks. Lower- and middle-income countries will have free access to the stockpile, but other countries must reimburse the vaccine's cost to GAVI.
Reuters (12/5) 
LinkedIn Twitter Facebook Email
Industry News & Practice
Regeneron reports data from trial testing pozelimab in PNH
Regeneron Pharmaceuticals unveiled topline data from a midstage trial assessing its candidate REGN3918, or pozelimab, as a treatment for paroxysmal nocturnal hemoglobinuria. Results showed that after being treated once a week, patients' lactate dehydrogenase levels returned to normal by the eighth week.
Seeking Alpha (12/5) 
LinkedIn Twitter Facebook Email
Dynavx, Albertsons partner in distribution deal for HBV vaccine
Dynavax Technologies' vaccine HEPLISAV-B will soon become available at 1,700 pharmacies after the pharma firm entered a partnership deal with Albertsons. HEPLISAV-B is approved as a preventive treatment against hepatitis B virus in adults aged 18 and up.
Seeking Alpha (12/5) 
LinkedIn Twitter Facebook Email
Government & Regulatory
Chinese regulators OK launch of CAR-T trial for B-ALL, B-cell NHL
China's National Medical Product Administration approved CASI Pharmaceuticals' application, filed by Juventas Cell Therapy, its partner, to launch the trial for its investigational therapy candidate CNCT19, or CD19 chimeric antigen receptor T-cell therapy, to treat relapsed or refractory B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. Enrollment is slated to begin early next year.
Seeking Alpha (12/4) 
LinkedIn Twitter Facebook Email
Association News
AABB Molecular Testing Standards Committee seeks input to guide updates to 5th edition
The AABB Standards for Molecular Testing for Red Cell, Platelet and Neutrophil Antigens, 5th Edition, will take effect Oct. 1, 2020. The Molecular Testing Standards Committee hopes to engage members in developing the 5th edition and asks interested parties to submit comments to help shape these updates. The Committee will review all responses during its next meeting, to be held in January 2020. AABB will continue to hold the 60-day open comment period following the release of the proposed Standards, currently scheduled to begin in February.
LinkedIn Twitter Facebook Email
Learn more about AABB®:
Homepage | Join AABB | Conferences
Marketplace | AABB CareerLink
powered by
Clinical Lab Scientist
Manager, Scientific Affairs
TERUMO BCT - Lakewood, CO, US
Medical Technologist
Technical Director (Remote)
ICCBBA - Remote, US
Madam, you ask me how I compose. I compose sitting down.
Pyotr Ilyich Tchaikovsky,
LinkedIn Twitter Facebook Email
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2019 SmartBrief, Inc.®
Privacy Policy (updated May 25, 2018) |  Legal Information